FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL						
OMB Number:	3235-0287					
Estimated average burden						
hours per response:	0.5					

_	Check this box if no longer subject to Section
[]	16. Form 4 or Form 5 obligations may continue
$\overline{}$	Con Instruction 1/h)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person Robinson William G Jr				<u>C</u>	2. Issuer Name and Ticker or Trading Symbol CLOVER HEALTH INVESTMENTS, CORP. /DE [CLOV]									onship of Repor ill applicable) Director Officer (give	Ü	on(s) to Is	10% Owi	ner pecify below)
(Last) (First) (Middle) C/O CLOVER HEALTH INVESTMENTS, CORP. 3401 MALLORY LANE, SUITE 210					3. Date of Earliest Transaction (Month/Day/Year) 09/22/2022								1	below)				
(Street) FRANKLIN (City)	TN (State)	37 (Zi	067	4.	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individ	dividual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
D)			2. Transaction Date (Month/Day/Year)							rities Acquired (A) or Dispo tr. 3, 4 and 5)		·	Beneficially Own Following Repor		Form: Di	wnership m: Direct (D) or rect (I) (Instr. 4)	7. Nature of Indirect Beneficial	
						(Month/Day/Year)		Code	v	Amount		(A) or (D)		Transaction(s) (Instr. 3 and 4)				Ownership (Instr. 4)
Class A Common Stock				09/2	09/22/2022		M		27,1	00	A	(1)	54,200)		D		
Class A Common Stock			09/2	09/22/2022		A		20,27	71(2)	A	\$0	74,471			D			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	nstr. 3) Conversion or Exercise Price of Derivative Date (Month/Day/Year) Execution Date, if any (Month/Day/Year)			Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of S Underlying Derivative S (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number derivative Securitie Beneficia Owned Following	e Ces Fally D	Ownership Form:	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
	Security			Code	v	(A)	(D)	Date Exercisa	ble [Expiration Date	Title		Amount or Number of Shares	nount or Reporte		ion(s)		
Restricted Stock Unit	(1)	09/22/2022		M			27,100	(3)		(3)		A Common Stock	27,100	\$0	0		D	

Explanation of Responses:

- 1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock upon settlement for no consideration.
- 2. Represents shares of Class A common stock underlying a time-based RSUs. One hundred percent of the RSUs will vest on the first anniversary of the Date of Grant, subject to the Reporting Person's continued service as a member of the Company's Board of Directors through such date.
- 3. The remaining number of the shares subject to the RSU award vested on the date of the 2022 Annual Meeting.

Remarks:

Exhibit List 24 1- Power of Attorney

/s/ Jamie L. Reynoso, Attorney-in-Fact 09/26/2022 for William G. Robinson Jr.

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

The undersigned as a Section 16 reporting person of Clover Health Investments, Corp. (the "Company"), hereby constitutes and appoints Scott J. Leffler, Joseph R. Martin, Jamie L. Reynoso and Jessica Kirkland, and each of them, the undersigned's true and lawful attorney-in-fact to:

- (1) execute, deliver and file for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of the Company, Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and the rules thereunder;
- (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5, complete and execute any amendment or amendments thereto, and file such form with the SEC and any stock exchange or similar authority;
- (3) seek or obtain, as the undersigned's representative and on the undersigned's behalf, information on transactions in the Company's securities from any third party, including brokers, employee benefit plan administrators and trustees, and the undersigned hereby authorizes any such person to release any such information to the undersigned and approves and ratifies any such release of information; and
- (4) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act. The undersigned further acknowledges and agrees that the attorney-in-fact and the Company are relying on written and oral information provided by the undersigned to complete such forms and the undersigned is responsible for reviewing the completed forms prior to their filing. The attorney-in-fact and the Company are not responsible for any errors or omissions in such filings. The attorney-in-fact and the Company are not responsible for determining whether or not the transactions reported could be matched with any other transactions for the purpose of determining liability for short-swing profits under Section 16(b).

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the Company and the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this $\underline{16}^{th}$ day of September, 2022.

/s/ William G. Robinson Jr.
William G. Robinson, Jr.